

# AID expression levels determine the extent of *cMyc* oncogenic translocations and the incidence of B cell tumor development

Makiko Takizawa,<sup>1</sup> Helena Tolarová,<sup>1</sup> Zhiyu Li,<sup>1</sup> Wendy Dubois,<sup>2</sup> Susan Lim,<sup>1</sup> Elsa Callen,<sup>3</sup> Sonia Franco,<sup>4</sup> Maria Mosaico,<sup>5</sup> Lionel Feigenbaum,<sup>5</sup> Frederick W. Alt,<sup>4</sup> André Nussenzweig,<sup>3</sup> Michael Potter,<sup>2</sup> and Rafael Casellas<sup>1</sup>

<sup>1</sup>Genomic Integrity and Immunity, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD 20892

<sup>2</sup>Laboratory of Genetics and <sup>3</sup>Experimental Immunology, National Cancer Institute (NCI), NIH, Bethesda, MD 20892

<sup>4</sup>Children's Hospital, CBR Institute for Biomedical Research, and Howard Hughes Medical Institute, Boston, MA 02115

<sup>5</sup>Laboratory Animal Science Program, SAIC, NCI, NIH, Frederick, MD 21702

**Immunoglobulin (Ig) isotype switching is a recombination event that changes the constant domain of antibody genes and is catalyzed by activation-induced cytidine deaminase (AID). Upon recruitment to Ig genes, AID deaminates cytidines at switch (S) recombination sites, leading to the formation of DNA breaks. In addition to their role in isotype switching, AID-induced lesions promote *Igh-cMyc* chromosomal translocations and tumor development. However, *cMyc* translocations are also present in lymphocytes from healthy humans and mice, and thus, it remains unclear whether AID directly contributes to the dynamics of B cell transformation. Using a plasmacytoma mouse model, we show that *AID*<sup>+/-</sup> mice have reduced AID expression levels and display haploinsufficiency both in the context of isotype switching and plasmacytomagenesis. At the Ig loci, *AID*<sup>+/-</sup> lymphocytes show impaired intra- and inter-switch recombination, and a substantial decrease in the frequency of S mutations and chromosomal breaks. In *AID*<sup>+/-</sup> mice, these defects correlate with a marked decrease in the accumulation of B cell clones carrying *Igh-cMyc* translocations during tumor latency. These results thus provide a causality link between the extent of AID enzymatic activity, the number of emerging *Igh-cMyc*-translocated cells, and the incidence of B cell transformation.**

## CORRESPONDENCE

Michael Potter:  
potter@helix.nih.gov  
OR  
Rafael Casellas:  
casellar@mail.nih.gov

Upon antigen encounter, activated B cells often replace their heavy chain constant domain ( $C_H\mu$ ) with one of a set of downstream  $C_H$  exons ( $C_H\gamma$ ,  $C_H\epsilon$ , or  $C_H\alpha$ ) in a process known as class switch recombination (CSR). This intra-chromosomal recombination event occurs between highly repetitive switch (S) sequences located upstream of each  $C_H$  gene, with the exception of  $C_H\delta$ . CSR is targeted to specific S regions by 5' I promoters that mediate germline or sterile S- $C_H$  transcription (1), and by 5' and 3' heavy chain enhancers that promote S-S synapses (2). These mechanisms cooperate to render S domains accessible to activation-induced cytidine deaminase (AID) (3, 4), a B cell-specific enzyme encoded by the *Aicda* gene that deaminates cytidine residues to uracils on both

strands of S region DNA, resulting in U:G mismatches (5).

Uracils are recognized and removed by uracil DNA glycosylase and mismatch repair enzymes (6, 7), leading ultimately to the formation of DNA double-strand breaks (6, 8, 9). These DNA lesions are processed by the nonhomologous end-joining proteins and other repair mechanisms that ensure efficient recombination (10). If unrepaired, however, AID-mediated DNA breaks can become substrates for chromosomal translocations that often juxtapose protooncogenes to the Ig loci. Canonical *Igh-cMyc* translocations, for instance, are the hallmark of both Burkitt's lymphomas in humans (T(8;14)) and plasmacytomas in mice (T(12;15)) (11).

The role of AID in the etiology of *Igh-cMyc* chromosomal translocations was implicated by

The online version of this article contains supplemental material.

genetic experiments using  $AID^{-/-}$  mice carrying IL-6 or Bcl-xL transgenes (12, 13). In both cases, deletion of AID resulted in the absence of canonical *cMyc* translocations. In H2AX $^{-/-}$  B cells, AID was also required for CSR-mediated translocations (14). In addition, several lines of evidence indicate that AID somatic hypermutation (SHM) activity may also promote tumor development by targeting non-Ig genes (15–17). Using a plasmacytoma mouse model, we now demonstrate that the extent of AID activity influences the incidence of B cell tumor development by directly determining the number of lymphocytes undergoing *Igh-cMyc* chromosomal translocations during tumor latency.

## RESULTS AND DISCUSSION

### Delayed plasma cell tumor development in AID heterozygous mice

Pristane injection of BALB/c mice expressing Bcl-2 or Bcl-xL transgenes leads to the rapid induction of plasmacytomas carrying canonical *Igh-cMyc* translocations (13, 18). In the absence of AID, BALB/c-Bcl-xL mice display a reduced incidence of plasmacytomas carrying translocations that are nonreciprocal and do not involve S regions (13). To investigate whether AID gene dosage contributes to tumor susceptibility, we induced plasmacytomas in groups of BALB/c-Bcl-xL mice carrying one ( $AID^{+/-}$ ) or two copies of AID ( $AID^{+/+}$ ). After pristane injection, the presence of plasma cell tumors in peritoneal oil granulomas was diagnosed by the appearance of tumor cells in the ascites. We found that  $AID^{+/-}$  mice developed tumors phenotypically indistinguishable from  $AID^{+/+}$  as judged by histological features, the expression of mature plasma cell markers, or tumor recovery in transplantation assays (Fig. 1 A and not depicted). However, there was a clear difference in tumor incidence between the two groups of mice: the median tumor latency in  $AID^{+/-}$  animals ( $n = 96$ ) was 102 d, whereas that of  $AID^{+/+}$  mice ( $n = 41$ ) was 82 d ( $P = 0.01$ ; Fig. 1 B, left). In the absence of Bcl-xL, plasmacytomagenesis was, as expected, markedly delayed in both groups of mice. Still, AID heterozygous mice showed decreased tumor incidence relative to AID wild-type counterparts (Fig. 1 B, right). These results thus reveal a straight correlation between AID gene dosage and the incidence of plasma cell tumor development.

### Reduced CSR in stimulated $AID^{+/-}$ B cells

The results described in the previous paragraph imply that AID activity is compromised in  $AID^{+/-}$  mice. To confirm this, we stimulated  $AID^{+/-}$  and  $AID^{+/+}$  splenic B cells with LPS and IL-4, which induce AID transcription and CSR primarily to IgG1. Real-time PCR and Western blot analyses showed lower AID mRNA and protein in activated  $AID^{+/-}$  lymphocytes compared with controls (Fig. 2 A). This reduction in AID expression levels was correlated with impaired switching, as indicated by a 40–50% decrease in surface IgG1 expression in heterozygous cells relative to wild-type ( $P < 0.0005$ ; Fig. 2 B). B cell activation with LPS and  $\alpha$ - $\delta$ -dextran or IFN- $\gamma$  also showed a statistically significant

decrease in  $\gamma$ 3 and  $\gamma$ 2a recombination between  $AID^{+/+}$  and  $AID^{+/-}$  lymphocytes ( $P = 0.01$  and  $P < 0.0005$  for  $\gamma$ 3 and  $\gamma$ 2, respectively;  $n = 5$ ; Fig. 2 B). CSR levels have been shown to be closely associated with cell division (19, 20). We examined cell proliferation in  $AID^{+/-}$  and wild-type cultures by CFSE labeling, and IgG1 switching was simultaneously determined by flow cytometry. We found no obvious differences in cell division between the two groups of B cells (Fig. 2 C, histograms). However,  $\gamma$ 1 switching in  $AID^{+/-}$  lymphocytes lagged  $AID^{+/+}$  by approximately two cell cycles (Fig. 2 C, graph), thus confirming that CSR levels are compromised in  $AID^{+/-}$  cells.

Lymphocytes activated for CSR undergo frequent AID-dependent S deletions, predominantly at S $\mu$  (21, 22). To measure the incidence of intra-S $\mu$  deletions, we generated IgM $^{+}$  hybridoma clones from  $AID^{+/+}$  and  $AID^{+/-}$  B cells stimulated for 96 h in the presence of LPS and IL-4. Southern blotting showed a threefold reduction in intra-S $\mu$  deletions in B cells carrying a single copy of *Aicda*, as only 9 out of 79  $AID^{+/-}$  clones (11%) displayed structural alterations in S $\mu$ , whereas S deletions were present in 43 out of 110  $AID^{+/+}$  clones analyzed (39%;  $P < 0.0005$ ; Fig. 2 D).

Reduced inter- and intra-switch recombination in  $AID^{+/-}$  cells could conceivably result from monoallelic expression of *Aicda*. Under this scenario, up to 50% of  $AID^{+/-}$  B cells would transcribe the neomycin-deleted allele, leading to a complete absence of AID expression and activity in 50% of cultured cells. To directly evaluate this idea, we monitored AID gene transcription by single-cell RT-PCR (23). By this assay, only the untargeted *Aicda* allele is amplified using PCR primers specific for AID exons 2 and 3, which are deleted by neomycin insertion in the targeted allele (3). We detected AID in 185 out of 192 single  $AID^{+/-}$  B cells assayed (Fig. 2 E), a result that clearly demonstrates *Aicda* transcription to be biallelic. We conclude that CSR defects in  $AID^{+/-}$  cultures result from a reduction in overall AID expression levels.

AID deamination leads to nucleotide substitutions at S domains (24, 25), primarily as a result of DNA replication over uracils and error-prone repair activity (6). To measure S mutation frequency, we cloned and sequenced the 5' end of S $\mu$  from  $AID^{+/-}$  and wild-type lymphocytes stimulated with LPS and IL-4 for 96 h. Sequencing analysis showed a striking reduction in S $\mu$  mutations in heterozygous cells ( $P < 0.0005$ ; Fig. 2 F). The calculated mutation frequency in  $AID^{+/-}$  cells was in fact not significantly higher than the PCR error rate determined using  $AID^{-/-}$  controls ( $P = 0.2$ ; Fig. 2 F). Collectively, our data reveal that the frequency of S mutation and recombination in stimulated B cells is determined, at least in part, by AID gene dosage.


### Reduced AID activity in $AID^{+/-}$ mice during the immune response

We next examined AID activity during the humoral immune response.  $AID^{+/-}$  and control BALB/c littermates were immunized in the front footpads by subcutaneous injection of 50  $\mu$ g of chicken  $\gamma$  globulin (CGG) in the presence of


complete adjuvant. CSR levels were then monitored in germinal centers (GCs) from axillary and brachial lymph nodes 7 d after immunization. In agreement with the B cell culture results, we found fewer IgG1 B220<sup>+</sup>CD95<sup>high</sup> GC cells in AID<sup>+/-</sup> mice relative to controls ( $P = 0.04$ ; Fig. 3 A). Notably, the disparity in CSR levels between the two strains of mice was not as striking as that seen in ex vivo cultures. This might be explained by the combined facts that switched cells accumulate over time as a function of the cell cycle (Fig. 2 C), and that B cell recruitment to and proliferation in GCs is extensive and asynchronized (26).

To evaluate whether reduced AID expression levels affected V gene hypermutation, we next cloned and sequenced the 5' end of the JH-E $\mu$  intron (downstream of rearranged V<sub>H</sub>DJ<sub>H4</sub> genes) from sorted B220<sup>+</sup>CD95<sup>high</sup> GC cells. This analysis showed a comparable hypermutation frequency between the two groups of mice ( $P = 0.5$ ). Notably, AID<sup>+/-</sup> GCs harbored fewer clones carrying multiple mutations (Fig. 3 B), suggesting a reduction in the accumulation of point mutations in heterozygous cells. To directly evaluate whether

affinity maturation was affected as a function of AID expression, AID<sup>+/-</sup> and control mice were immunized intraperitoneally with hapten (4-hydroxy-3-nitrophenyl)acetyl (NP) conjugated to CGG (NP<sub>25</sub>-CGG) adsorbed to alum. The affinity of serum antibodies for NP was then monitored 7 and 28 d after immunization by ELISA. In this assay, low affinity antibodies were captured using a high density NP-substituted BSA (NP<sub>30</sub>-BSA), whereas high affinity antibodies were specifically monitored with NP<sub>7</sub>-BSA. Low affinity IgG1 serum levels were not different between the two strains of mice ( $P = 0.8$ ; Fig. 3 C, left). Nonetheless, we found a statistically significant reduction of high affinity anti-NP antibodies in AID<sup>+/-</sup> mice compared with wild-type counterparts ( $P = 0.006$ ; Fig. 3 C, right). Thus, it seems likely that under conditions of limited AID activity, fewer AID<sup>+/-</sup> B cell clones develop high affinity antibodies during the immune response. Based both on the CSR and SHM data, we conclude that the extent of AID enzymatic activity during the immune response is moderately affected in AID<sup>+/-</sup> mice.



**Figure 1. Haploinsufficiency in plasma cell tumor development in AID<sup>+/-</sup> mice.** (A) Photomicrographs of plasma cell tumors arising in BALB/c-Bcl-xL AID<sup>+/+</sup> and BALB/c-Bcl-xL AID<sup>+/-</sup> mice show no significant variations in plasma cell morphology. Bar, 20  $\mu$ m. (B, left) Incidence of plasma cell tumors in the presence of Bcl-xL as determined by the histological appearance of foci, with each containing 50 or more atypical plasma cells (red squares, plasma cell tumors in 36 out of 41 AID<sup>+/+</sup> mice injected with pristane; black circles, plasma cell tumors in 58 out of 96 AID<sup>+/-</sup> mice). (right) Plasmacytoma development in AID<sup>+/+</sup> ( $n = 16$ ) and AID<sup>+/-</sup> ( $n = 39$ ) mice in the absence of Bcl-xL.




**Figure 2. Reduced AID activity in AID<sup>+/-</sup> B cells.** (A) AID mRNA (graph, AID<sup>+/+</sup> and AID<sup>+/-</sup>; n = 5) and protein (AID<sup>+/+</sup>, AID<sup>+/-</sup>, and AID<sup>-/-</sup>), as measured by real-time PCR and Western blotting. Error bars represent the mean ± SD. (B, left) IgG1 switching (pseudocolor plot) profiles in wild-type and AID<sup>+/-</sup> B cells activated *in vivo*, as determined by flow cytometry. (right) Mean switching to IgG1, IgG3, and IgG2a. Values represent the mean ± SD (n = 5). Antibodies were B220-PerCP-Cy5.5 and IgG1-PE. Dead cells were gated out using DAPI. (C) Flow cytometric measurement of cell proliferation and IgG1 switching on CFSE-labeled B cells activated for 96 h with LPS + IL-4. The graph represents percentages of γ1 switching at each cell division (n = 2). Error bars represent the mean ± SD. (D) The percentage of intra-switch deletions as determined by Southern blotting on hybridomas generated from AID<sup>+/+</sup> and AID<sup>+/-</sup> lymphocytes activated for 96 h in the presence of LPS + IL-4. Intact Sμ domains result in a 6.9-kb band, whereas smaller bands (stars) represent intra-switch deletions. (E) Analysis of AID gene expression by single-cell RT-PCR (137 bp) from sorted LPS + IL-4-activated B cells. (F) Sμ mutation frequency in AID<sup>+/+</sup>, AID<sup>+/-</sup>, and AID<sup>-/-</sup> activated B cells. Pie chart segments are proportional to the number of sequences carrying an equal number of mutations (indicated on the periphery). The total number of sequences is portrayed in the middle of each chart, and mutation frequency (calculated as the total mutations per total base pairs sequenced) and p-values are shown below the charts.

### Diminished chromosome 12 breaks and *Igh-cMyc* translocation-bearing cells in *AID*<sup>+/-</sup> mice

Plasmacytomagenesis in pristane-treated mice is a multistep process initiated by the deregulation of *cMyc* upon translocation to the *Igh* loci. Fully malignant monoclonal tumors are thought to arise from a polyclonal pool of premalignant B cells bearing *cMyc* translocations (27). We reasoned that delayed tumor development in *AID*<sup>+/-</sup> mice might result from a reduction in the number of clones carrying *cMyc* translocations. To investigate this, Bcl-xL transgenic *AID*<sup>+/+</sup> and *AID*<sup>+/-</sup> mice were injected with pristane, and the presence of translocation-bearing cells before the onset of malignancy (approximately day 45; Fig. 1 B) was determined by long-distance PCR using nested primers specific for S $\mu$ , S $\gamma$ 2a, S $\alpha$ , and *cMyc* intron 1 (Fig. 4 A, diagram). At days 25 and 35 after pristane treatment, canonical translocations were amplified from DNA samples representing  $5 \times 10^5$  mononuclear cells isolated from Peyer's patches, mesenteric lymph nodes, or oil granuloma. DNA from three (day 35) or five (day 25) *AID*<sup>+/+</sup> or *AID*<sup>+/-</sup> mice was analyzed. The specificity of the


PCR was evaluated by Southern blotting using both *Igh*- and *cMyc*-specific probes, and unique T(12;15)-positive clones were distinguished by their size (from 1–4 kb; Fig. 4 A) and sequencing analysis (Fig. 4 B; and Table S1, available at <http://www.jem.org/cgi/content/full/jem.20081007/DC1>). At day 25, an analysis of 57 PCR samples from *AID*<sup>+/+</sup> mice revealed nine distinct translocations (16%, or 1 T(12;15)/ $10^5$  cells; Fig. 4 A). In contrast, only 2 out of 67 *AID*<sup>+/-</sup> samples (3%, or 0.2 T(12;15)/ $10^5$  cells) showed bona fide *Igh-cMyc* translocations ( $P = 0.01$ ; Fig. 4 A and Table S1). Similarly, 22 out of 69 (30%) *AID*<sup>+/+</sup> samples showed translocations at day 35 after pristane treatment, whereas we detected only 7 translocations in 72 (10%) *AID*<sup>+/-</sup> samples assayed (2 vs. 0.6 T(12;15)/ $10^5$  cells, respectively;  $P = 0.001$ ; Fig. 4 A). In both groups of mice, the majority of the translocations were mapped to S $\alpha$  (~70%; Table S1), a feature that suggestively reflects the prevalence of IgA CSR in gut-associated lymphoid tissues (23). Thus, compared with wild-type controls, *AID*<sup>+/-</sup> mice display a substantial reduction in the number of translocation-bearing cells emerging upon tumor induction.



**Figure 3. Reduced AID activity in *AID*<sup>+/-</sup> mice during the immune response.** (A) Measurement of IgG1 levels in GCs from *AID*<sup>+/+</sup> and *AID*<sup>+/-</sup> mice. Values represent the mean  $\pm$  SD ( $n = 5$ ). (B) Somatic hypermutation as determined by sequencing the JH4 intron from *AID*<sup>+/+</sup>, *AID*<sup>+/-</sup>, and *AID*<sup>-/-</sup> GC cells. (C) ELISA analysis of serum from five *AID*<sup>+/+</sup> and *AID*<sup>+/-</sup> mice immunized with NP-*CGG*. IgG1 antibodies displaying low affinity for NP were captured in this assay using NP<sub>30</sub>-BSA, whereas high affinity antibodies were monitored with NP<sub>7</sub>-BSA, as described in Results and discussion. Horizontal bars represent the mean.

S recombination and *Igh-cMyc* translocations originate from DNA double-strand breaks targeting S domains in activated B cells (14, 28). To evaluate whether the frequency of S DNA breaks was affected in AID heterozygous mice, we bred the AID-deleted allele onto the H2AX<sup>-/-</sup> background,

where a large number of unrepaired CSR lesions progress into chromosome breaks (14, 28, 29). These lesions, detected in metaphase spreads by fluorescence in situ hybridization (FISH) using VH- and C $\alpha$ -specific probes, are good indicators of the relative frequency of S DNA breaks occurring in



**Figure 4. Paucity of translocation-bearing clones and CSR-induced DNA breaks in AID<sup>-/-</sup> mice.** (A) *Igh-cMyc* chromosomal translocations in BALB/c-Bcl-xL AID<sup>+/+</sup> and BALB/c-Bcl-xL AID<sup>+/-</sup> mice (three mice per time point) were amplified by PCR 25 or 35 d after pristane injection using nested primers (arrows) specific for *cMyc* intron 1 and *Igh* C $\mu$ , C $\gamma$ 2b, and C $\alpha$  constant domains. PCR products were analyzed by Southern blotting using *cMyc*- and *Igh*-specific probes. (B) PCR products appearing multiple times were sequenced and counted once if they represented a single clone. (C) *Igh* FISH in metaphase spreads from AID<sup>+/+</sup>H2AX<sup>-/-</sup> and AID<sup>+/-</sup>H2AX<sup>-/-</sup> B cells activated for CSR. (left) The loss of the red VH signal with an intact green C $\alpha$  signal (micrograph) denotes a chromosome 12 break. (right) Total number of breaks observed for each strain (metaphases analyzed are indicated on top of each bar).

G1 (14, 28, 29). Analysis of metaphase spreads from AID<sup>+/+</sup>H2AX<sup>-/-</sup> and AID<sup>+/-</sup>H2AX<sup>-/-</sup> B cells stimulated with LPS and IL-4 for 96 h showed a direct correlation between the frequency of CSR breaks and AID gene dosage. Although 17.5% of all AID<sup>+/+</sup>H2AX<sup>-/-</sup> metaphases displayed split VH/C $\alpha$  signals, only 9% of all AID<sup>+/-</sup>H2AX<sup>-/-</sup> metaphases showed evidence of chromosome 12 breaks (Fig. 4 C). We conclude that S domain DNA breaks are diminished in AID heterozygous B cells.

We have shown that the absence of a single copy of *Aicda* affects the rate of intrachromosomal recombination and interchromosomal translocations involving the *Igh* loci. This haploinsufficiency for AID is likely explained by the marked reduction in the frequency of formation and availability of S-DNA lesions in AID<sup>+/-</sup> cells. The strong inference is that AID protein content falls below a critical threshold in lymphocytes carrying a single copy of *Aicda*. Such a threshold might be imposed by mechanisms controlling nuclear AID (30, 31), which represents a minor fraction of total AID protein in activated B cells (32). Alternatively, error-free repair pathways, which have been shown to inhibit both CSR and SHM (17, 33), may compromise AID activity to a greater extent under conditions of limited AID transcription. Regardless of the mechanism at work, our findings demonstrate that AID expression levels directly determine the extent of AID-dependent DNA remodeling events, including chromosomal translocations. Thus, AID expression levels appear to determine the incidence of plasmacytomagenesis by specifying the number of *cMyc* translocation-bearing clones emerging during tumor induction. Overt transformation of such clones may subsequently rely on a mistargeted SHM, which as we have shown is also dependent on the amount of AID.

Our previous work revealed that noncanonical T(12;15) translocations can occur in the absence of AID (13). On the other hand, canonical translocations targeting S region DNA and *cMyc* intron 1 absolutely require AID enzymatic activity (12, 13). We now extend these results by showing that AID expression levels directly determine the rate of canonical translocations emerging during tumor induction in vivo. Ramiro et al. have similarly shown that *cMyc* translocations can be induced in an AID-dependent manner in vitro (28). In that study, translocations were rarely present under physiological AID levels in LPS- and IL-4-stimulated B cells, whereas AID overexpression dramatically increased their frequency (28). In like manner, *Igh-cMyc* translocations are produced to a disproportionately high degree in stimulated B lymphocytes deficient for microRNA 155 (34), which normally suppresses the steady state of *Aicda* mRNA and AID protein content (34, 35). We find it noteworthy that although the frequency of off-target translocations is highly sensitive to AID expression levels, in vivo on-target SHM and CSR are only mildly affected by AID overexpression (34) or underexpression (this report). It seems likely that AID enzymatic activity is differentially constrained at on and off targets. The unraveling of such regulatory mechanisms might help clarify

how S DNA breaks promote physiological recombination or pathological translocations in the B cell compartment.

## MATERIALS AND METHODS

**Tumor induction.** SV40-E $\mu$ -Bcl-xL and AID<sup>-/-</sup> (a gift from T. Honjo, Kyoto University, Kyoto, Japan) mice were backcrossed for 11 generations onto BALB/c mice in a conventional facility. Bcl-xL-AID<sup>+/+</sup> and Bcl-xL-AID<sup>+/-</sup> mice were given 0.5 ml of pristane oil intraperitoneally at 8 wk of age, followed by a second injection of pristane 60 d later. BALB/c-Bcl-xL AID<sup>+/+</sup> and AID<sup>+/-</sup> mice were intraperitoneally inoculated with 0.4 or 0.5 ml pristane (Aldrich Chemicals) at 2 mo of age. Using Wright-Giemsa-stained cytochrome preparations of ascites, plasma cell tumors were diagnosed by the presence of 10 or more tumor cells per field. All animal experiments were performed according to the NIH guidelines for laboratory animals and were approved by the Scientific Committee of the NIAMS and NCI Animal Facilities.

**B cell culture.** To induce S recombination ex vivo, B lymphocytes were isolated from spleens by immunomagnetic depletion using CD43 MACS beads (Miltenyi Biotec). Purified cells were then activated in B cell media (RPMI 1640, 10% FCS, 1 $\times$  antibiotic-antimycotic, 1% glutamine, 1 $\times$  nonessential amino acids, 1% sodium pyruvate, 14.2 M 2- $\beta$ -mercaptoethanol, and 10 mM HEPES) for 72 or 96 h in the presence of 25  $\mu$ g/ml LPS (*Escherichia coli* 0111:B4; Sigma-Aldrich) and 5 ng/ml IL-4 (Invitrogen) to induce switching to IgG1, 2.5 ng/ml  $\alpha$ - $\delta$ -dextran (Fina Biosolutions) for IgG3 CSR, or 2 ng/ml IFN- $\gamma$  (PeproTech) for IgG2a switching. Cell proliferation was monitored by CFSE staining according to the manufacturer's instructions (Invitrogen).

**Flow cytometry.** Unless otherwise stated, the following antibodies were obtained from BD Biosciences: B220-PerCP-Cy5.5, Fab'2-IgM-Cy5 (Jackson ImmunoResearch Laboratories), IgG1-PE, IgG3-biotin, streptavidin-PE, and IgG2a-FITC. Apoptotic cells were gated out using TO-PRO-3 (Invitrogen) or DAPI (Sigma-Aldrich). Flow cytometers used were the FACSCalibur (BD Biosciences) and the Cyan (Dako), and a MoFlo instrument (Dako) was used for cell sorting. Flow cytometry data were analyzed with FlowJo software (Tree Star, Inc.).

**qRT-PCR.** RNA was extracted with RNAqueous-Micro (Ambion) and treated with DNaseI. cDNA was synthesized, and the level of endogenous AID transcripts was monitored by real-time PCR with the following primers: PrimerBank-mAID5' (5'-gccaccttgcacaagctct-3') and PrimerBank-mAID3' (5'-ccggcagctcatagcac-3'). cDNA was normalized based on Ku80 mRNA with the following primers: QRT-mKu80-5' (5'-CTTCCTGGACGCCCTGATTG-3') and QRT-mKu80-3' (5'-GCTGCGGAGGTCAGTGAAC-3').

**Western blotting.** To detect AID protein, cultured B cells in the presence of LPS and IL-4 were lysed with NP-40 lysis buffer (10 mM Tris-HCl [pH 8], 150 mM NaCl, 0.5% NP-40, 5 mM EDTA, 1 mM DTT, and protease inhibitor cocktail). 50  $\mu$ g per well of lysates was separated using NuPAGE 4–12% Bis-Tris gels (Invitrogen). Gels were transferred to polyvinylidene fluoride membranes (Invitrogen) and analyzed by immunoblotting AID antiserum (a gift from J. Stavnezer, University of Massachusetts, Worcester, MA) and anti- $\beta$ -actin antibody (Millipore). For secondary antibodies, goat anti-mouse IgG (Millipore) and goat anti-rabbit IgG conjugated with horseradish peroxidase (HRP; Abcam) were used. Blots were visualized using the ECL-PLUS kit (GE Healthcare).

**S $\mu$  mutations.** Mutations at S $\mu$  were determined by amplifying genomic DNA from LPS + IL-4-activated (96 h) B cells with primers S $\mu$ (B) (5'-gtaggaggaccaggctaaag-3') and S $\mu$ (D) (5'-cagtcagctgtaggcagtaga-3') at 95°C for 30 s, 60°C for 30 s, and 72°C for 30 s (product = 650 bp). The final product was ligated into ZeroBlunt vector (Invitrogen), and positives clones were sequenced with M13 primers.

**FISH analysis.** At 72 h, cultured B cells were arrested at mitosis with 100 ng/ml colcemid (Roche), swollen in prewarmed 0.075 M KCl for 15 min at

37°C and fixed by methanol/acetic acid treatment, and dropped in microscope slides using a humidity chamber (Thermotron). Slides were denatured in 75°C 70% formamide for 7 min; hybridized with following probes overnight at 37°C; washed, dehydrated, and stained with DAPI; and mounted with Vectashield (Vector Laboratories). BAC probes containing the IgH C $\alpha$  and Vh regions were labeled by digoxigenin and a biotin nick translation kit (Roche), and were detected by antidigoxigenin FITC antibody (Roche), and Alexa Fluor 568-conjugated streptavidin (Invitrogen). FISH images were captured using an epifluorescence microscope (DMRB Leitz; Leica) and a charge-coupled device camera (model C4742-95; Hamamatsu Photonics).

**Hybridoma analysis.** Analysis of CD43<sup>-</sup> MACS-isolated B cells were stimulated with LPS + IL-4 for 96 h and fused to the SP2/0Ag-14 myeloma cell line. IgM-secreting clones, as determined by ELISA, were expanded in culture for further analysis. Genomic DNA was prepared and Southern blot analysis was performed using standard techniques.

**Detection of Igh-cMyc translocations and plasma cell tumors.** Tissue samples were harvested 25 or 35 d after pristane injection. DNA samples from three (day 35) and five (day 25) mice were prepared as follows: Peyer's patches (three samples per mouse), mesenteric lymph nodes (two samples per mouse), and oil granuloma (two samples per mouse). Tissues were collected in separate tubes and DNA was isolated individually. The sensitivity of the translocation PCR was measured using serial dilution of positive control cells with wild-type mouse liver cells and calculated as >6.25 T(12;15) positive cells/10<sup>5</sup> negative cells. PCR products were separated on 1% agarose gels and denatured for 15 min in the presence of 0.4 M NaOH before being transferred to nylon membranes. The Southern blot probe was amplified and labeled by the ECL Direct Labeling and Detection System (GE Healthcare). Probe primer sequences were as follows: c-myc forward, 5'-gct-agcgcagtgaggagaag-3'; c-myc reverse, 5'-gagccactgcaccagaga-3'; C $\mu$  forward, 5'-agccagtgtctcagagga-3'; C $\mu$  reverse, 5'-cttaagcagcagggcta-3'; C $\gamma$ 2 $\beta$  forward, 5'-aagtcagacctcactgca-3'; C $\gamma$ 2 $\beta$  reverse, 5'-cagaggatcat-gtcttgatg-3'; C $\alpha$  forward, 5'-tgctgctgatctcagtc-3'; and C $\alpha$  reverse, 5'-ttgaacatgacctcagtgatc-3'.

**ELISA.** Five AID<sup>+/+</sup> and AID<sup>+/-</sup> mice were immunized intraperitoneally with 100  $\mu$ g NP<sub>25</sub>-CGG precipitated in Alum (Thermo Fisher Scientific). Sera were collected before and at 7 or 28 d after immunization. Serum anti-NP levels were measured by standard ELISA. Plates were coated with 5  $\mu$ g/ml NP<sub>30</sub>-BSA or NP<sub>7</sub>-BSA in PBS. Serum samples were diluted, and bound antibody was detected using HRP-conjugated anti-mouse IgG (Bethyl) followed by 3,3',5,5'-tetramethylbenzidine treatment.

**Online supplemental material.** Table S1 shows the translocation PCR/Southern blot results from AID<sup>+/+</sup>, AID<sup>+/-</sup>, and AID<sup>-/-</sup> mice carrying Bcl-xL. Online supplemental material is available at <http://www.jem.org/cgi/content/full/jem.20081007/DC1>.

We thank Janet Stavnezer for anti-AID antisera, Tasuku Honjo for AID<sup>-/-</sup> mice, Siegfried Janz and Beverly Mock for helpful comments, and Jim Simone for technical assistance.

This research was supported in part by the Intramural Research Program of NIAMS and NCI of the NIH.

The authors declare no competing financial interests.

Submitted: 8 May 2008

Accepted: 2 July 2008

## REFERENCES

- Stavnezer, J., J.E. Guikema, and C.E. Schrader. 2008. Mechanism and regulation of class switch recombination. *Annu. Rev. Immunol.* 26:261–292.
- Wuerffel, R., L. Wang, F. Grigera, J. Manis, E. Selsing, T. Perlot, F.W. Alt, M. Cogne, E. Pinaud, and A.L. Kenter. 2007. S-S synapsis during class switch recombination is promoted by distantly located transcriptional elements and activation-induced deaminase. *Immunity.* 27:711–722.
- Muramatsu, M., K. Kinoshita, S. Fagarasan, S. Yamada, Y. Shinkai, and T. Honjo. 2000. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. *Cell.* 102:553–563.
- Revy, P., T. Muto, Y. Levy, F. Geissmann, A. Plebani, O. Sanal, N. Catalan, M. Forveille, R. Dufourcq-Labeolouse, A. Gennery, et al. 2000. Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). *Cell.* 102:565–575.
- Di Noia, J., and M.S. Neuberger. 2002. Altering the pathway of immunoglobulin hypermutation by inhibiting uracil-DNA glycosylase. *Nature.* 419:43–48.
- Rada, C., J.M. Di Noia, and M.S. Neuberger. 2004. Mismatch recognition and uracil excision provide complementary paths to both Ig switching and the A/T-focused phase of somatic mutation. *Mol. Cell.* 16:163–171.
- Bardwell, P.D., C.J. Woo, K. Wei, Z. Li, A. Martin, S.Z. Sack, T. Parris, W. Edelmann, and M.D. Scharff. 2004. Altered somatic hypermutation and reduced class-switch recombination in exonuclease 1-mutant mice. *Nat. Immunol.* 5:224–229.
- Guikema, J.E., E.K. Linehan, D. Tsuchimoto, Y. Nakabeppu, P.R. Strauss, J. Stavnezer, and C.E. Schrader. 2007. APE1- and APE2-dependent DNA breaks in immunoglobulin class switch recombination. *J. Exp. Med.* 204:3017–3026.
- Larson, E.D., W.J. Cummings, D.W. Bednarski, and N. Maizels. 2005. MRE11/RAD50 cleaves DNA in the AID/UNG-dependent pathway of immunoglobulin gene diversification. *Mol. Cell.* 20:367–375.
- Yan, C.T., C. Boboila, E.K. Souza, S. Franco, T.R. Hickernell, M. Murphy, S. Gumaste, M. Geyer, A.A. Zarrin, J.P. Manis, et al. 2007. IgH class switching and translocations use a robust non-classical end-joining pathway. *Nature.* 449:478–482.
- Küppers, R. 2005. Mechanisms of B-cell lymphoma pathogenesis. *Nat. Rev. Cancer.* 5:251–262.
- Ramiro, A.R., M. Jankovic, T. Eisenreich, S. Difilippantonio, S. Chen-Kiang, M. Muramatsu, T. Honjo, A. Nussenzweig, and M.C. Nussenzweig. 2004. AID is required for c-myc/IgH chromosome translocations in vivo. *Cell.* 118:431–438.
- Kovalchuk, A.L., W. duBois, E. Mushinski, N.E. McNeil, C. Hirt, C.F. Qi, Z. Li, S. Janz, T. Honjo, M. Muramatsu, et al. 2007. AID-deficient Bcl-xL transgenic mice develop delayed atypical plasma cell tumors with unusual Ig/Myc chromosomal rearrangements. *J. Exp. Med.* 204:2989–3001.
- Franco, S., M. Gostissa, S. Zha, D.B. Lombard, M.M. Murphy, A.A. Zarrin, C. Yan, S. Tepsuporn, J.C. Morales, M.M. Adams, et al. 2006. H2AX prevents DNA breaks from progressing to chromosome breaks and translocations. *Mol. Cell.* 21:201–214.
- Pasqualucci, L., G. Bhagat, M. Jankovic, M. Compagno, P. Smith, M. Muramatsu, T. Honjo, H.C. Morse III, M.C. Nussenzweig, and R. Dalla-Favera. 2008. AID is required for germinal center-derived lymphomagenesis. *Nat. Genet.* 40:108–112.
- Okazaki, I.M., H. Hai, N. Kakazu, S. Yamada, M. Muramatsu, K. Kinoshita, and T. Honjo. 2003. Constitutive expression of AID leads to tumorigenesis. *J. Exp. Med.* 197:1173–1181.
- Liu, M., J.L. Duke, D.J. Richter, C.G. Vinuesa, C.C. Goodnow, S.H. Kleinstein, and D.G. Schatz. 2008. Two levels of protection for the B cell genome during somatic hypermutation. *Nature.* 451:841–845.
- Silva, S., A.L. Kovalchuk, J.S. Kim, G. Klein, and S. Janz. 2003. BCL2 accelerates inflammation-induced BALB/c plasmacytomas and promotes novel tumors with coexisting T(12;15) and T(6;15) translocations. *Cancer Res.* 63:8656–8663.
- Hasbold, J., L.M. Corcoran, D.M. Tarlinton, S.G. Tangye, and P.D. Hodgkin. 2004. Evidence from the generation of immunoglobulin G-secreting cells that stochastic mechanisms regulate lymphocyte differentiation. *Nat. Immunol.* 5:55–63.
- Rush, J.S., M. Liu, V.H. Odegard, S. Unniraman, and D.G. Schatz. 2005. Expression of activation-induced cytidine deaminase is regulated by cell division, providing a mechanistic basis for division-linked class switch recombination. *Proc. Natl. Acad. Sci. USA.* 102:13242–13247.



21. Reina-San-Martin, B., S. Difilippantonio, L. Hanitsch, R.F. Masilamani, A. Nussenzweig, and M.C. Nussenzweig. 2003. H2AX is required for recombination between immunoglobulin switch regions but not for intra-switch region recombination or somatic hypermutation. *J. Exp. Med.* 197:1767–1778.
22. Dudley, D.D., J.P. Manis, A.A. Zarrin, L. Kaylor, M. Tian, and F.W. Alt. 2002. Internal IgH class switch region deletions are position-independent and enhanced by AID expression. *Proc. Natl. Acad. Sci. USA.* 99:9984–9989.
23. Crouch, E.E., Z. Li, M. Takizawa, S. Fichtner-Feigl, P. Gourzi, C. Montano, L. Feigenbaum, P. Wilson, S. Janz, F.N. Papavasiliou, and R. Casellas. 2007. Regulation of AID expression in the immune response. *J. Exp. Med.* 204:1145–1156.
24. Petersen, S., R. Casellas, B. Reina-San-Martin, H.T. Chen, M.J. Difilippantonio, P.C. Wilson, L. Hanitsch, A. Celeste, M. Muramatsu, D.R. Pilch, et al. 2001. AID is required to initiate Nbs1/gamma-H2AX focus formation and mutations at sites of class switching. *Nature.* 414:660–665.
25. Nagaoka, H., M. Muramatsu, N. Yamamura, K. Kinoshita, and T. Honjo. 2002. Activation-induced deaminase (AID)-directed hypermutation in the immunoglobulin Smu region: implication of AID involvement in a common step of class switch recombination and somatic hypermutation. *J. Exp. Med.* 195:529–534.
26. Schwickert, T.A., R.L. Lindquist, G. Shakhar, G. Livshits, D. Skokos, M.H. Kosco-Vilbois, M.L. Dustin, and M.C. Nussenzweig. 2007. In vivo imaging of germinal centres reveals a dynamic open structure. *Nature.* 446:83–87.
27. Potter, M. 2003. Neoplastic development in plasma cells. *Immunol. Rev.* 194:177–195.
28. Ramiro, A.R., M. Jankovic, E. Callen, S. Difilippantonio, H.T. Chen, K.M. McBride, T.R. Eisenreich, J. Chen, R.A. Dickins, S.W. Lowe, et al. 2006. Role of genomic instability and p53 in AID-induced c-myc-Igh translocations. *Nature.* 440:105–109.
29. Callen, E., M. Jankovic, S. Difilippantonio, J.A. Daniel, H.T. Chen, A. Celeste, M. Pellegrini, K. McBride, D. Wangsa, A.L. Bredemeyer, et al. 2007. ATM prevents the persistence and propagation of chromosome breaks in lymphocytes. *Cell.* 130:63–75.
30. McBride, K.M., V. Barreto, A.R. Ramiro, P. Stavropoulos, and M.C. Nussenzweig. 2004. Somatic hypermutation is limited by CRM1-dependent nuclear export of activation-induced deaminase. *J. Exp. Med.* 199:1235–1244.
31. Brar, S.S., M. Watson, and M. Diaz. 2004. Activation-induced cytosine deaminase (AID) is actively exported out of the nucleus but retained by the induction of DNA breaks. *J. Biol. Chem.* 279:26395–26401.
32. Rada, C., J.M. Jarvis, and C. Milstein. 2002. AID-GFP chimeric protein increases hypermutation of Ig genes with no evidence of nuclear localization. *Proc. Natl. Acad. Sci. USA.* 99:7003–7008.
33. Wu, X., and J. Stavnezer. 2007. DNA polymerase  $\beta$  is able to repair breaks in switch regions and plays an inhibitory role during immunoglobulin class switch recombination. *J. Exp. Med.* 204:1677–1689.
34. Dorsett, Y., K.M. McBride, M. Jankovic, A. Gazumyan, T. Thai, D.F. Robbani, M. Di Virgilio, B. Reina San-Martin, G. Heidkamp, T.A. Schwickert, et al. 2008. MicroRNA-155 suppresses activation-induced cytidine deaminase-mediated Myc-Igh translocation. *Immunity.* 28:630–638.
35. Teng, G., P. Hakimpour, P. Landgraf, A. Rice, T. Tusch, R. Casellas, and F.N. Papavasiliou. 2008. MicroRNA-155 is a negative regulator of activation-induced cytidine deaminase. *Immunity.* 28:621–629.